NASDAQ:PRPO - Precipio Stock Price, Forecast & News

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Precipio shares reverse split on the morning of Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

Precipio (NASDAQ:PRPO) released its earnings results on Wednesday, November, 13th. The biotechnology company reported ($0.31) EPS for the quarter. The biotechnology company earned $0.78 million during the quarter. Precipio had a negative return on equity of 94.75% and a negative net margin of 525.32%. View Precipio's Earnings History.

Precipio is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Precipio.

1 analysts have issued 1-year price targets for Precipio's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Precipio's stock price to reach $4.00 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View Analyst Price Targets for Precipio.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Precipio.

News headlines about PRPO stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Precipio earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Precipio.

Some companies that are related to Precipio include HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Scientific Industries (SCND), Aethlon Medical (AEMD), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Portola Pharmaceuticals (PTLA), Biocept (BIOC), MannKind (MNKD), Jaguar Health (JAGX), Inpixon (INPX), TrovaGene (TROV), ACADIA Pharmaceuticals (ACAD), AEterna Zentaris (AEZS), Avid Bioservices (CDMO) and Cellectar Biosciences (CLRB).

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRPO stock can currently be purchased for approximately $2.09.

Precipio has a market capitalization of $16.76 million and generates $2.86 million in revenue each year. Precipio employs 42 workers across the globe.View Additional Information About Precipio.

The official website for Precipio is http://www.precipiodx.com/.

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]